Purisys is a global leader in custom synthesis of active pharmaceutical ingredients. We support pharma & biotech companies with APIs, reference standards, controlled substances, cannabinoids, psychedelics, and cGMP clinical & niche commercial CDMO services. Formed as a spin-off from Noramco in 2019, Purisys began manufacturing in 1979 as part of Johnson & Johnson. WORLD LEADER IN PHARMACEUTICAL CANNABINOIDS, PSYCHEDELICS & REFERENCE STANDARDS Purisys produces 50+ major and minor cannabinoids, as well as degradants, metabolites & analytical standards to support our customers in this growing field. In addition, we have DEA licenses for several Psychedelic basic classes and have produced GMP psilocybin and Psilocin supporting customers’ R&D programs. We have multiple DMFs, including Dronabinol (#20682), CBD (#33223), Nabilone (#35408), and have produced other cannabinoids used worldwide in IND/IMPD/NDA/ANDA filings. CUSTOM API and DRUG DEVELOPMENT & MANUFACTURING (CDMO) SERVICES FOR PHARMA & BIOTECH For clients seeking preclinical-to-commercial APIs, we provide comprehensive development, analytical and manufacturing services - including full-service clinical-to-commercial small volume & orphan drug commercial API synthesis in our FDA-inspected GMP manufacturing suites. Our custom synthesis projects include difficult-to-manufacture APIs (controlled substances, injectable-grade APIs, HPAPIs and environmentally sensitive APIs). IN-STOCK REFERENCE STANDARDS AND CUSTOM SYNTHESIS SERVICES Purisys stocks 250+ reference standards with structural elucidation and comprehensive analytical data. We ship reference standards to 30+ countries on 6 continents. CAPABILITIES: • Cannabinoid and psychedelic APIs suitable for registered pharma research to treat, cure, or prevent disease • In-stock standards; custom synthesis & qualification • Excipient compatibility & formulation & solid state • cGMP manufacturing • HPAPI & labile molecule development • Method development